The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Open accessAbstract
Purpose: Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation prolongs the serum concentration of IL-10 without changing the immunologic profile. This phase I study sought to determine the safety and antitumor activity of AM0010. Patients and Methods: Patients with selected advanced solid tumors were treated with AM0010 in a dose-escalation study, which was followed by a renal cell cancer (RCC) dose-expansion cohort. AM0010 was self-administered subcutaneously at doses of 1 to 40 μg/kg once per day. Primary end points were safety and tolerability; clinical activity and immune activation were secondary end points. Results: In the dose-escalation and -expansion cohorts, 33 and 18 patients, respectively, were treated with daily subcutaneous injection of AM0010. AM0010 was tolerated in a heavily pretreated patient population. Treatment-related adverse events (AEs) included anemia, fatigue, thrombocytopenia, fever, and injection site reactions. Grade 3 to 4 nonhematopoietic treatment-related AEs, including rash (n = 2) and transaminitis (n = 1), were observed in five of 33 patients. Grade 3 to 4 anemia or thrombocytopenia was observed in five patients. Most treatment-related AEs were transient or reversible. AM0010 led to systemic immune activation with elevated immune-stimulatory cytokines and reduced transforming growth factor beta in the serum. Partial responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RCC treated at 20 μg/kg (overall response rate, 27%). Prolonged stable disease of at least 4 months was observed in four patients, including one with colorectal cancer with disease stabilization for 20 months. Conclusion: AM0010 has an acceptable toxicity profile with early evidence of antitumor activity, particularly in RCC. These data support the further evaluation of AM0010 both alone and in combination with other immune therapies and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Contextual Regulation of Inflammation: A Duet by Transforming Growth Factor-β and Interleukin-10
Li, M. O., & Flavell, R. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.003 · Cited by 501
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322
Self-citationRole of IL-10 for induction of anemia during inflammation
Tilg, H., Ulmer, H., Kaser, A., & Weiss, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.2204 · Cited by 181
Cited by
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Biology and therapeutic potential of interleukin-10
Saraiva, M., Vieira, P., & O’Garra, A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190418 · Cited by 1,118
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Metadata
- Authors
- Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., Mumm, J. B., Chan, I. H., Bendell, J. C., Bauer, T. M., Colen, R. R., Hong, D. S., Van Vlasselaer, P., Tannir, N. M., Oft, M., & Infante, J. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-10-10
- Volume
- 34
- Issue
- 29
- Pages
- 3562-3569
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2514572740
- Cited by
- 222
- References
- 7
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.2016.68.1106
- The paper
- Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., Mumm, J. B., Chan, I. H., Bendell, J. C., Bauer, T. M., Colen, R. R., Hong, D. S., Van Vlasselaer, P., Tannir, N. M., Oft, M., & Infante, J. R. (2016). Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.68.1106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.